Peyronie disease in association with carvedilol: a case report.
Beta blockade is associated with the onset and progression of Peyronie disease (PD). To date, there has not been a report of PD occurring with the alpha/beta blocker carvedilol. It remains unproven but likely that carvedilol was the cause of the PD in the patient described in this case. It is hypothesized that because of carvedilol's vasodilating alpha adrenergic receptor stimulation and its anti-inflammatory effect, PD occurs less frequently with carvedilol than with other beta blockers. However, in this case the protective properties of carvedilol, like vasodilation and the anti-inflammatory effect, may not be sufficient to overcome its vasoconstricting beta adrenergic receptor blockade.
Bell
David S H
DS
Southside Endocrinology, Birmingham, AL 35205, USA. dshbell@yahoo.com
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D002227:Carbazoles / Q000009:adverse effects*; D000077261:Carvedilol; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000139:chemically induced* / Q000503:physiopathology; D011412:Propanolamines / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol